Redmile Group, LLC's Form 4 filing
Fate Therapeutics Inc (FATE) · filed Apr 21, 2023
- Accession no.
- 0001104659-23-048557
- Filed
- Apr 21, 2023, 9:55 PM ET
- Trade date
- Apr 20-21, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $1.71M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Redmile Group, LLCCIK 0001425738 | Director, 10% Owner |
| Green JeremyCIK 0001650527 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 20, 2023 | Common Stock | PPurchaseAcquired | +20,000 | $5.99 | +$119,800 | 12,879,119 | Indirect | |
| Apr 21, 2023 | Common Stock | PPurchaseAcquired | +256,639 | $6.18 | +$1,586,029.02 | 13,135,758 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.